Oncotype DX Recurrence Score in premenopausal women

In the past 20 years, clinicians have shifted away from relying solely on clinicopathologic indicators toward increasing use of multigene expression assays in guiding treatment decisions regarding adjuvant chemotherapy for early-stage hormone receptor (HR)-positive, HER2-negative breast cancer. Onco...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shiliang, Fitzsimmons, Kasey C., Hurvitz, Sara A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918761/
https://www.ncbi.nlm.nih.gov/pubmed/35295864
http://dx.doi.org/10.1177/17588359221081077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918761/
https://www.ncbi.nlm.nih.gov/pubmed/35295864
http://dx.doi.org/10.1177/17588359221081077

Ejemplares similares